Trebananib Withdrawn Phase 2 Trials for Transitional Cell Carcinoma Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01907308Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma